Acupoint injection therapy
Acupoint injection therapy has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 27, 2026: “Efficacy and safety of acupuncture-related therapies in improving insulin resistance, reproductive endocrine outcomes, and ovarian morphology in polycystic ovary syndrome:…”.
1 paper studies it1 findingUpdated
See all 1 papers on acupoint injection therapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
- 1 lab in 1 country
- Funder: National Key Research and Development Program of China
What did studies of acupoint injection therapy find?
1Studies of acupoint injection therapy measured one outcome, HOMA-IR.
HOMA-IR
downin humans1
1 study
HOMA-IR
downin humans1
Acupoint injection therapy decreases HOMA-IR in humans (polycystic ovary syndrome) (MD = 2.20, 95% CI 0.44-3.96).
“Acupoint injection therapy (AIT) and acupuncture plus moxibustion (Acu + Moxi) significantly reduced HOMA-IR (MD = 2.20, 95% CI 0.44-3.96; MD = 1.06, 95% CI 0.28-1.84).”
Reviewpolycystic ovary syndrome
Frontiers in endocrinology